poisar

Stocks · News reference

Neurocrine Biosciences Announces New Survey Results for INGREZZA

Fiscal.ai

Neurocrine Biosciences released findings from a new survey indicating that adults with tardive dyskinesia report fewer work and school disruptions when treated with INGREZZA.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

    DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.